News & Topics
News&Topics

2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2021.03.29
SymBio submits partial change application to extend the shelf life of TREAKISYM Ready-To-Dilute (RTD) Formulation
2021.03.25
Notice of Shareholder Voting Results for the16th Ordinary General Meeting of Shareholders
2021.03.25
SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.03.25
SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.03.24
Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers
2021.03.24
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2021.03.24
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2021.03.23
SymBio receives approval for use of TREAKISYM in combination with rituximab and polatuzumab vedotin as treatment for relapsed or refractory diffuse large B-cell lymphoma
2021.03.23
SymBio receives approval for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
2021.03.11
SymBio submits IND Application for Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV for treatment of Pediatric Adenovirus Infection
2021.03.03
Information on Shareholders' Meeting: Updated the Page
2021.02.26
Chimerix Announces FDA Extends PDUFA Date of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox to July 7, 2021
2021.02.25
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2021.02.22
Results of Phase III Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2021.02.04
Analyst Report[Update report] (Shared Research)
2021.02.04
3 Year Mid-Range Plan: FY 2021 to FY 2023
2021.02.04
Notice Concerning Non-Operating Income
2021.02.04
Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated)
2021.01.28
Collaborative research with the Institute of Medical Science, the University of Tokyo, to explore new indications for bendamustine and rigosertib
2021.01.12
Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation